Cansativa

Cansativa is a GMP and GDP-certified pharmaceutical company that operates a B2B platform for medical cannabis. Founded in 2017, it supplies products and services to pharmacies, doctors, patients and suppliers across Germany and Europe, combining pharmaceutical manufacturing with medical cannabis import, wholesale and distribution. The firm describes itself as the market leader in Germany's medicinal cannabis industry.

The company's platform functions as an infrastructure layer for the European cannabis market, connecting participants in the sector with established brands and pharmaceutical-grade products. Its technical work spans GMP/GDP-certified production, medical cannabis import and wholesale, and the B2B platform infrastructure itself. Operating sectors include medical cannabis, pharmaceuticals, healthcare, pharmacy and wholesale pharmaceutical distribution.

Cansativa raised $15m in a Series B round. Its stated focus is on professionalising and simplifying access to medical cannabis within Germany's healthcare system, with an emphasis on quality, reliability and the setting of new industry standards in pharmaceutical-grade cannabis distribution.